Table 4.
Incremental cost-effectiveness over 30 years of routine adolescent MenB-FHbp vaccination strategies
| No vaccine | Strategy 1 | Strategy 2 | Strategy 3 | |
|---|---|---|---|---|
| Vaccination at age 14 with 75% uptake | Vaccination at age 17 with 75% uptake | Vaccination at age 17 with 30% uptake | ||
| Total disease cases | 3974 | − 688 | − 1033 | − 575 |
| Without complications | 3124 | − 541 | − 809 | − 451 |
| With complications | 594 | − 115 | − 168 | − 94 |
| Total deaths | 256 | − 33 | − 55 | − 30 |
| Total costs | $234,870,873 | $963,462,826 | $1,035,258,328 | $404,008,939 |
| Direct costs | $43,422,199 | $1,001,609,686 | $1,093,091,508 | $435,775,514 |
| Productivity costs | $191,448,675 | − $38,146,860 | − $57,833,180 | − $31,766,575 |
| Vaccination costs | $0 | $1,008,367,723 | $1,103,135,636 | $441,254,255 |
| Life-years lost | 12,461 | − 2140 | − 3538 | − 1945 |
| QALYs lost | 6017 | − 987 | − 1512 | − 825 |
| Cost per QALY saved | $975,954 | $684,654 | $489,700 |
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year